Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments

JAMA

Volumn 305, Issue 10, 2011, Pages 1008-1017

  Roseman, Michelle ^a,b   Milette, Katherine ^a,b   Bero, Lisa A ^c,d   Coyne, James C ^e,f   Lexchin, Joel ^g,h,i   Turner, Erick H ^j   Thombs, Brett D ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g YORK UNIVERSITY   (Canada)

^h UNIVERSITY HEALTH NETWORK   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLOGY; CLINICAL RESEARCH; CONFLICT OF INTEREST; CONSUMER ADVOCACY; DATA BASE; DATA EXTRACTION; DRUG INDUSTRY; DRUG RESEARCH; ENDOCRINOLOGY; FINANCIAL MANAGEMENT; FUNDING; GASTROENTEROLOGY; HUMAN; INFORMATION PROCESSING; MEDICAL RESEARCH; META ANALYSIS (TOPIC); ONCOLOGY; PRIORITY JOURNAL; PUBLICATION; REVIEW; SYSTEMATIC REVIEW;

EID: 79952390925     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.257     Document Type: Review

References (69)

1. Our conflicted medical journals. New York Times. July 23, 2006:WK11.
2. van Kolfschooten F. Conflicts of interest: can you believe what you read? Nature. 2002;416(6879):360-363.
3. DeAngelis CD, Fontanarosa PB. Impugning the integrity of medical science: the adverse effects of industry influence. JAMA. 2008;299(15):1833-1835. (Pubitemid 351549977)
4. Sismondo S. How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Soc Sci Med. 2008;66(9):1909-1914. (Pubitemid 351454041)
5. Bero LA, Rennie D. Influences on the quality of published drug studies. Int J Technol Assess Health Care. 1996;12(2):209-237. (Pubitemid 26195521)
6. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-260.
7. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med. 2008;5(11):e217.
8. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003; 326(7400):1171-1173. (Pubitemid 36649049)
9. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006;163(2):185-194. (Pubitemid 44480836)
10. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290(7):921-928. (Pubitemid 37430464)
11. Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials. 2008;29(2):109-113. (Pubitemid 351248768)
12. Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med. 2007;4(6):e184.
13. Lexchin J, Bero LA, Djulbegovic B, ClarkO. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003; 326(7400):1167-1170. (Pubitemid 36649048)
14. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289(4): 454-465. (Pubitemid 36119966)
15. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ. 2002;325(7358):249.
16. Yaphe J, Edman R, Knishkowy B, Herman J. The association between funding by commercial interests and study outcome in randomized controlled drug trials. Fam Pract. 2001;18(6):565-568. (Pubitemid 34026576)
17. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med. 1998;338(2):101-106. (Pubitemid 28042274)
18. Friedman LS, Richter ED. Relationship between conflicts of interest and research results. J Gen Intern Med. 2004;19(1):51-56.
19. Tatsioni A, Siontis GC, Ioannidis JP. Partisan perspectives in the medical literature: a study of high frequency editorialists favoring hormone replacement therapy. J Gen Intern Med. 2010;25(9):914-919.
20. Wang AT, McCoy CP, Murad MH, Montori VM. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ. 2010;340:c1344.
21. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.
22. Hopewell S, Clarke M, Moher D, et al; CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008; 371(9609):281-283.
23. Drazen JM, Van Der Weyden MB, Sahni P, et al. Uniform format for disclosure of competing interests in ICMJE journals. JAMA. 2010;303(1):75-76.
24. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
25. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
26. Patsopoulos NA, Analatos AA, Ioannidis JP. Relative citation impact of various study designs in the health sciences. JAMA. 2005;293(19):2362-2366. (Pubitemid 40676758)
27. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323(7308):334-336. (Pubitemid 32744465)
28. Barnes DE, Bero LA. Why review articles on the health effects of passive smoking reach different conclusions. JAMA. 1998;279(19):1566-1570. (Pubitemid 28233013)
29. Yank V, Rennie D, Bero LA. Financial ties and concordance between results and conclusions in metaanalyses: retrospective cohort study. BMJ. 2007; 335(7631):1202-1205. (Pubitemid 350273305)
30. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews compared with industry supported metaanalyses and other meta-analyses of the same drugs: systematic review. BMJ. 2006;333(7572):782.
31. IMS Health Inc. Top 15 global therapeutic classes, 2008. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/ Top-Line-Data/Global-Top-15-Therapy-Classes.pdf. Accessed February 13, 2011.
32. Institute for Scientific Information. Journal citation reports: 2008 JCR science edition. http://www.isiknowledge.com/jcr/. Accessed February 13, 2011.
33. U.S. Food and Drug Administration. Orange Book: approved drug products with therapeutic equivalence evaluations. http://www.accessdata.fda.gov/scripts/ cder/ob/default.cfm. Accessed February 13, 2011.
34. de Almeida JR, Al Khabori M, Guyatt GH, et al. Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis. JAMA. 2009;302(9):985-993.
35. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301(18):1909-1919.
36. Häuser W, Bernardy K, Uçeyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA. 2009;301(2):198-209.
37. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet. 2009;374(9691):712-719.
38. Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765-1772.
39. Heerspink HJL, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2009;373(9668):1009-1015.
40. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151(6):394-403.
41. Fuccio L, Zagari RM, Eusebi LH, et al. Metaanalysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med. 2009;151(2):121-128.
42. Quant EC, Jeste SS, Muni RH, Cape AV, Bhussar MK, Peleg AY. The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy: a meta-analysis. BMJ. 2009;339:b3354.
43. Hayward G, Thompson M, Heneghan C, Perera R, Del Mar C, Glasziou P. Corticosteroids for pain relief in sore throat: systematic review and meta-analysis. BMJ. 2009;339:b2976.
44. Shun-Shin M, Thompson M, Heneghan C, Perera R, Harnden A, Mant D. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ. 2009;339:b3172.
45. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol. 2009;27(20):3277-3283.
46. Di Maio M, Chiodini P, Georgoulias V, et al. Metaanalysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(11):1836-1843.
47. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009;10(6):559-568.
48. Ho KM, Tan JA. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a doseresponse meta-analysis. Circulation. 2009;119 (14):1853-1866.
49. De Luca G, Ucci G, Cassetti E, Marino P. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol. 2009; 53(18):1668-1673.
50. Verdecchia P, Angeli F, Cavallini C, et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J. 2009;30(6):679-688.
51. Wijesinghe M, Weatherall M, Perrin K, Harwood M, Beasley R. Risk of mortality associated with formoterol: a systematic review and meta-analysis. Eur Respir J. 2009;34(4):803-811.
52. Sindi A, Todd DC, Nair P. Antiinflammatory effects of long-acting β2-agonists in patients with asthma: a systematic review and metaanalysis. Chest. 2009;136(1):145-154.
53. Tassinari D, Scarpi E, Sartori S, et al. Second-line treatments in non-small cell lung cancer: a systematic review of literature and metaanalysis of randomized clinical trials. Chest. 2009;135(6):1596-1609.
54. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32(10):1924-1929.
55. Hartweg J, Farmer AJ, Holman RR, Neil A. Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes. Curr Opin Lipidol. 2009; 20(1):30-38.
56. Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia. 2009;52(10):1990-2000.
57. Ford AC, Talley NJ, Schoenfeld PS, Quigley EMM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009;58(3): 367-378.
58. Ravipati M, Katragadda S, Swaminathan PD, Molnar J, Zarling E. Pharmacotherapy plus endoscopic intervention is more effective than pharmacotherapy or endoscopy alone in the secondary prevention of esophageal variceal bleeding: a meta-analysis of randomized, controlled trials. Gastrointest Endosc. 2009;70(4):658-664.e5.
59. Barkun AN, Martel M, Toubouti Y, Rahme E, Bardou M. Endoscopic hemostasis in peptic ulcer bleeding for patients with high-risk lesions: a series of meta-analyses. Gastrointest Endosc. 2009;69(4): 786-799.
60. Caslake R, Macleod A, Ives N, Stowe R, Counsell C. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. Cochrane Database Syst Rev. 2009;(4):CD006661.
61. Koch MW, Polman SK. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev. 2009;(4):CD006453.
62. Perez MI, Musini VM, Wright JM. Effect of early treatment with anti-hypertensive drugs on short and long-term mortality in patients with an acute cardiovascular event. Cochrane Database Syst Rev. 2009; (4):CD006743.
63. Higgins JPT, Altman DG, eds, Higgins JPT, Green S, eds. Chapter 8: Assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2, Updated September 2009. http://www.cochrane-handbook.org. Accessed January 4, 2011.
64. Licurse A, Barber E, Joffe S, Gross C. The impact of disclosing financial ties in research and clinical care: a systematic review. Arch Intern Med. 2010;170 (8):675-682.
65. Chaudhry S, Schroter S, Smith R, Morris J. Does declaration of competing interests affect readers' perceptions? a randomised trial. BMJ. 2002;325(7377): 1391-1392. (Pubitemid 35477844)
66. Schroter S, Morris J, Chaudhry S, Smith R, Barratt H. Does the type of competing interest statement affect readers' perceptions of the credibility of research? randomised trial. BMJ. 2004;328(7442):742-743. (Pubitemid 38406427)
67. West S, King V, Carey TS, et al. Systems to Rate the Strength of Scientific Evidence. Rockville, MD: Agency for Healthcare Research and Quality; 2002. Evidence Report/Technology Assessment 47.
68. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews.BMC Med Res Methodol. 2007;7:10.
69. Bero LA. Accepting commercial sponsorship: disclosure helps - but is not a panacea. BMJ. 1999; 319(7211):653-654.